Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-19 01:11 CEST (UTC+2h)
BRB
Junior

Canada,
2018-01-03 21:42

Posting: # 18137
Views: 606
 

 FDA Draft guidance on Good ANDA Submission Practices [Regulatives / Guidelines]

Hi all,

The FDA just posted a draft guidance on Good ANDA submission practices:

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM591134.pdf


I found the section on deviations from product-specific guidances to be rather interesting such as:

A detailed justification for and data (such as their inclusion/exclusion criteria or demographic information) to support why their use of a particular study population does not affect their BE determination.

So for imatinib BE studies, which have been done in healthy subjects, but the guidance recommends to use patients, a detailed justification now needs to be provided?

BRB
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,384 posts in 3,905 threads, 1,172 registered users;
online 14 (1 registered, 13 guests [including 12 identified bots]).

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed